Publications
511 results found
Bhide AA, Cartwright R, Khullar V, et al., 2013, Biomarkers in overactive bladder (vol 24, pg 1065, 2013), INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1775-1777, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 1
Oelke M, Khullar V, Wijkstra H, 2013, Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials, WORLD JOURNAL OF UROLOGY, Vol: 31, Pages: 1093-1104, ISSN: 0724-4983
- Author Web Link
- Cite
- Citations: 23
Khullar V, Cambronero J, Angulo JC, et al., 2013, Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial, BMC Urology, Vol: 13, Pages: 1-9, ISSN: 1471-2490
BackgroundAntimuscarinic agents are currently the predominant treatment option for the clinical management of the symptoms of overactive bladder (OAB). However, low rates of persistence with these agents highlight the need for novel, effective and better-tolerated oral pharmacological agents. Mirabegron is a β3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics. In a randomized, double-blind, placebo- and active-controlled Phase 3 trial conducted in Europe and Australia (NCT00689104), mirabegron 50 mg and 100 mg resulted in statistically significant reductions from baseline to final visit, compared with placebo, in the co-primary end points – mean number of incontinence episodes/24 h and mean number of micturitions/24 h. We conducted a post hoc, subgroup analysis of this study in order to evaluate the efficacy of mirabegron in treatment-naïve patients and patients who had discontinued prior antimuscarinic therapy because of insufficient efficacy or poor tolerability.MethodsPatients were randomized to placebo, mirabegron 50 or 100 mg, or tolterodine extended release (ER) 4 mg orally, once-daily, for 12 weeks. For the post hoc analysis, the primary patient population was divided into the following subgroups: (1) patients who had not received any prior antimuscarinic OAB medication (treatment-naïve) and (2) patients who had received prior antimuscarinic OAB medication. The latter subgroup was further subdivided into patients who discontinued due to: (3) insufficient efficacy or (4) poor tolerability. Analysis of the co-primary efficacy endpoints by subgroup was performed using analysis of covariance with treatment group, subgroup, sex, geographical region, and subgroup-by-treatment interaction as fixed factors; and baseline value as a covariate.ResultsMirabegron, 50 mg and 100 mg once-daily, demonstrated similar improvements in the frequency of incontinence episodes and micturit
Bhide AA, Puccini F, Khullar V, et al., 2013, Botulinum neurotoxin type A injection of the pelvic floor muscle in pain due to spasticity: a review of the current literature, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1429-1434, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 15
Khullar V, Marschall-Kehrel D, Espuna-Pons M, et al., 2013, European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1529-1536, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 5
Vijaya G, Cartwright R, Derpapas A, et al., 2013, Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1523-1528, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 19
Sorrentino F, Tolton L, Cartwright R, et al., 2013, IS "ASYMPTOMATIC" BACTERIURIA ALWAYS ASYMPTOMATIC? ASSOCIATIONS BETWEEN INDIVIDUAL FEMALE LOWER URINARY TRACT SYMPTOMS AND SUBCLINICAL BACTERIAL INFECTION IN RANDOM URINE SAMPLES, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 699-700, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 1
Bray R, Cartwright R, Tikkinen K, et al., 2013, POST-PARTUM INCONTINENCE, BMI AND LOWER URINARY TRACT SYMPTOMS AT MIDILFE: 12-YEAR FOLLOW-UP OF A POPULATION-BASED PROSPECTIVE COHORT, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 591-592, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 1
Khullar V, Nitti V, Dmochowski R, et al., 2013, ONABOTULINUMTOXINA SIGNIFICANTLY DECREASES URINARY INCONTINENCE AND PROVIDES TREATMENT BENEFIT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER: A POOLED ANALYSIS OF TWO PHASE III, PLACEBO-CONTROLLED PIVOTAL TRIALS, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 765-765, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 1
Chapple C, Sievert K-D, MacDiarmid S, et al., 2013, OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial, EUROPEAN UROLOGY, Vol: 64, Pages: 249-256, ISSN: 0302-2838
- Author Web Link
- Cite
- Citations: 273
Dutta S, Cartwright R, Tikkinen K, et al., 2013, PREVALENCE AND RISK FACTORS FOR SYMPTOMATIC PELVIC ORGAN PROLAPSE USING THE ICIQ-VAGINAL SYMPTOMS QUESTIONNAIRE: RESULTS FROM THE TWINSUK ADULT TWIN REGISTRY, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 861-862, ISSN: 0733-2467
Vijaya G, Dutta S, Singh AU, et al., 2013, BACTERIA IN THE BLADDER WALL OF WOMEN WITH LOWER URINARY TRACT SYMPTOMS: AN INTERESTING FINDING, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 695-696, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 1
Tubaro A, Khullar V, Oelke M, et al., 2013, INTRA- AND INTER-READER VARIABILITY OF TRANSVAGINAL ULTRASOUND BLADDER WALL THICKNESS MEASUREMENTS: RESULTS FROM THE SHRINK STUDY, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 711-712, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 1
Angulo JC, Khullar V, Nitti VW, et al., 2013, Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder, ACTAS UROLOGICAS ESPANOLAS, Vol: 37, Pages: 640-651, ISSN: 0210-4806
- Author Web Link
- Cite
- Citations: 7
Nitti VW, Khullar V, van Kerrebroeck P, et al., 2013, Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies, International Journal of Clinical Practice, Vol: 67, Pages: 619-632, ISSN: 1368-5031
IntroductionTo examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results.MethodsThis prespecified pooled analysis of three randomised, double‐blind, placebo‐controlled, 12‐week studies, evaluated efficacy and safety of once‐daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and tolterodine ER 4 mg (safety analysis) for the treatment of symptoms of overactive bladder (OAB). Co‐primary efficacy measures were change from baseline to Final Visit in the mean number of incontinence episodes/24 h and mean number of micturitions/24 h. Key secondary efficacy end‐points included mean number of urgency episodes/24 h and mean volume voided/micturitions, while other end‐points included patient‐reported outcomes according to the Treatment Satisfaction‐Visual Analogue Scale (TS‐VAS) and responder analyses [dry rate (posttreatment), ≥ 50% reduction in incontinence episodes/24 h, ≤ 8 micturitions/24 h (post hoc analysis)]. The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate).ResultsMirabegron (50 and 100 mg once daily) demonstrated statistically significant improvements compared with placebo for the co‐primary end‐points, key secondary efficacy variables, TS‐VAS and responder analyses (all comparisons p < 0.05). Mirabegron is well tolerated and demonstrates a good safety profile. The most common AEs (≥ 3%) included hypertension, nasopharyngitis and urinary tract infection (UTI); the incidence of hypertensive events and UTIs decreased with increasing dose. For mirabegron, the incidence of the bothersome antimuscarinic AE, dry mouth, was at placebo level and of a lesser magnitude than tolterodine.ConclusionThe efficacy and safety of mirabegron are demonstrated in this
Digesu GA, Sadenghi P, Sharma S, et al., 2013, The importance of cystoscopy and bladder biopsy in women with refractory overactive bladder: the urogynaecologist's point of view?, EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, Vol: 169, Pages: 408-411, ISSN: 0301-2115
- Author Web Link
- Cite
- Citations: 7
Bhide AA, Cartwright R, Khullar V, et al., 2013, Biomarkers in overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1065-1072, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 60
Siddiqui E, Nitti V, Herschorn S, et al., 2013, Efficacy of mirabegron in patients with overactive bladder (OAB): Pre-specified analysis of three randomized, double-blind, placebo-controlled, Phase III studies, Annual Scientific Meeting of the British-Association-of-Urological-Surgeons (BAUS), Publisher: WILEY-BLACKWELL, Pages: 56-56, ISSN: 1464-4096
Chapple CR, Khullar V, Nitti VW, et al., 2013, EFFICACY OF MIRABEGRON IN OVERACTIVE BLADDER PATIENTS STRATIFIED BY SEVERITY OF BASELINE INCONTINENCE: A POST-HOC ANALYSIS OF POOLED DATA FROM 3 RANDOMISED PHASE 3 TRIALS, Publisher: SPRINGER LONDON LTD, Pages: S12-S13, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 1
Bray R, Cartwright R, Tikkinen K, et al., 2013, THE IMPACT OF POST-PARTUM INCONTINENCE ON LOWER URINARY TRACT SYMPTOMS: 12-YEAR FOLLOW-UP OF A POPULATION-BASED PROSPECTIVE COHORT, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S80-S81, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 1
Digesu A, Swift S, Ortiz OC, et al., 2013, THE FIGO ASSESSMENT SCORING SYSTEM (FASS) A NEW HOLISTIC CLASSIFICATION TOOL TO ASSESS WOMEN WITH PELVIC FLOOR DYSFUNCTION, Publisher: SPRINGER LONDON LTD, Pages: S15-S16, ISSN: 0937-3462
Khullar V, Sand P, Parsons M, et al., 2013, ONABOTULINUMTOXINA SIGNIFICANTLY REDUCES URINARY INCONTINENCE AND IMPROVES QUALITY OF LIFE IN FEMALE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S13-S14, ISSN: 0937-3462
Cartwright R, Kirby A, Thiagamoorthy G, et al., 2013, A SYSTEMATIC REVIEW AND META-ANALYSIS OF CANDIDATE GENE ASSOCIATION STUDIES OF LOWER URINARY TRACT SYMPTOMS AND PELVIC ORGAN PROLAPSE IN WOMEN., INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S2-S3, ISSN: 0937-3462
Sand P, Khullar V, Cardozo L, et al., 2013, EFFICACY OF MIRABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN FEMALE PATIENTS: PROSPECTIVE POOLED ANALYSIS OF 3 RANDOMISED PHASE 3 TRIALS, Publisher: SPRINGER LONDON LTD, Pages: S10-S12, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 1
Vijaya G, Puccini F, Dutta S, et al., 2013, IS THERE BACTERIAL INFECTION IN THE BLADDER WALL OF PATIENTS WITH REFRACTORY OVERACTIVE BLADDER?, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S79-S79, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 2
Derpapas A, Vijaya G, Digesu AG, et al., 2013, CLINICAL AND ULTRASONOGRAPHIC ASSESSMENT OF TWO DIFFERENT SURGICAL TECHNIQUES FOR POSTERIOR VAGINAL WALL REPAIR: A RANDOMISED CONTROL TRIAL., INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S127-S127, ISSN: 0937-3462
- Author Web Link
- Cite
- Citations: 1
Singh AU, Cartwright R, Bray R, et al., 2013, THE PREVALENCE OF LOWER URINARY TRACT SYMPTOMS IN WOMEN AGED 18-20: RESULTS FROM A POPULATION-BASED BIRTH COHORT, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S82-S82, ISSN: 0937-3462
Kirby A, Cartwright R, Tikkinen K, et al., 2013, CANDIDATE GENE ASSOCIATION STUDIES OF URINARY SYMPTOMS AND PELVIC ORGAN PROLAPSE IN WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS, Annual Meeting of the American-Urological-Association (AUA), Publisher: ELSEVIER SCIENCE INC, Pages: E47-E47, ISSN: 0022-5347
Derpapas A, Digesu AG, Hamady M, et al., 2013, Prevalence of pubovisceral muscle avulsion in a general gynecology cohort: A computed tomography (CT) study, NEUROUROLOGY AND URODYNAMICS, Vol: 32, Pages: 359-362, ISSN: 0733-2467
- Author Web Link
- Cite
- Citations: 6
Tikkinen K, Cartwright R, Kirby A, et al., 2013, CANDIDATE GENE ASSOCIATION STUDIES OF LOWER URINARY TRACT SYMPTOMS IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS, Annual Meeting of the American-Urological-Association (AUA), Publisher: ELSEVIER SCIENCE INC, Pages: E712-E712, ISSN: 0022-5347
- Author Web Link
- Cite
- Citations: 1
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.